|
DAY 3 | Wednesday 12th March
|
| 7.30 |
Registration & buffet breakfast in the exhibition area |
|
Morning plenary session
Decentralisation, offshoring and globalization: Where and how is biopharma generating greatest value?
|
| 9.00 |
Chair’s introduction
What does the R&D of 2015 look like – will it be heavily outsourced?
Dr Nahed Ahmed, Vice President, Program Management & Strategic Operations, Amgen, Inc
|
| 9.10 |
How much decentralization is enough and how should it be managed?
- Once you decentralize, how can you take advantage of still being big pharma?
- How to continue to take advantage of shared services
- What impact has the matrix system had on innovation, ability to develop long-term strategies and incorporate customer focus?
- How is the balance between strong functional areas and matrix-driven strategies managed optimally?
- What models are evolving for strategic partnering/ capability sourcing – what impact has it had on cost control, speed and responsiveness and productivity and what is the business case going forward?
- Combining outsourcing and partnership approaches
- What are the management and leadership issues?
- How much control should be retained in-house?
- Do we need different models for managing internal versus external research?
Dr Anthony Ford-Hutchinson, Executive Vice President & Franchise Head - Infectious Diseases & Vaccines, Merck Research Laboratories
|
| 9.35 |
Questions & discussion |
| 9.00 |
Keynote address
Evaluating globalization models: How do we take advantage of emerging science and talent in other countries?
- How, at a corporate level, should you think about expansion of R&D to developing countries?
- How do you weigh up the benefit:risk of doing discovery and development in tried and tested areas versus off-shoring?
- What are the pros and cons with respect to IP and quality
- What about trusted relationships?
- Ensuring that innovation and productivity is still accessible
- Developing world scientists will either become directly competitive or part of your vast army – which to chose?
- To what extent is can a truly end-to-end global business be achieved?
Dr Jeremy M. Levin, Senior Vice President, External Science, Technology & Licensing, Bristol-Myers Squibb Pharmaceutical Research Institute
|
| 10.05 |
Questions & discussion |
| 10.10 |
Case study
A new model for drug discovery: Establishing R&D in China
- Making the decision on build versus outsource/partnership approach
- Operationally, how do you weave your offshore sites into your existing business?
- What are the implications of moving trials offshore?
- Large scale multi-regional trials and their consequences
Dr Nader Fotouhi, Center Head, Nutley & Global Head of Discovery Technologies, Roche
|
| 10.35 |
Questions & discussion |
| 10.40 |
Morning coffee in the exhibition area |
| 11.10 |
Case study
Building a hub in India to meet long-term needs in clinical development
- Making the decision on build versus outsource/partnership approach
- Operationally, how do you weave your offshore sites into your existing business?
- What are the implications of moving trials offshore – large scale multi-regional trials and their consequences
P. K. Tandon, PhD, Senior Vice President, Global BioMedical Operations, Genzyme, Inc
|
| 11.35 |
Questions & discussion |
| 11.40 |
Challenges for China after entry in WTO - lessons from Beijing’s Health Forums
Dr Frank Douglas, Partner, PureTech Ventures & former Executive Director of Center of Biomedical Innovation, Massachusetts of Technology
|
| 12.05 |
12.05 Questions & discussion |
| 12.15 |
Panel discussion
What is the future for drug development in Asia and how will it impact R&D in the west?
- Examining the differences between E Europe / India / China – how are these markets growing in terms of innovation capability and knowledge base?
- How is this impacting the way western ‘customers’ and eastern ‘providers’ work together?
- How are goals and objectives changing?
- Capitalizing on data from patients in the developing world to get drugs approved in the US
- Informed consent and privacy issues
- How can western research institutions compete?
- How will the trend for increasing collaboration between Asian biopharma companies impact the competitiveness of western R&D?
|
| 1.00 |
Close of the R&D Leaders’ Forum Spring 2008 followed by lunch |
|
|
